Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based adult and pediatric cancer treatment and research institute, Dana-Farber Cancer Institute will administer Cellceutix Kevetrin to patients as part of the commenced clinical trials of the drug.
Subscribe to our email newsletter
Cellceutix chief scientific officer Krishna Menon said to date, everything is completed and Cellceutix is waiting for the host hospitals to begin dosing patients, which the company anticipates will happen shortly, but it is in the hospitals’ hands at the point.
"Dana-Farber is one of the few hospitals in the world that collects data ‘mapping’ the human genome as related to tumor profiling and the information that will be collected from our clinical trials of Kevetrin™ could prove an invaluable asset to those suffering from cancer and to Cellceutix," Menon added.
Kevetrin is an anti cancer drug that uses both wild and mutant types of p53,which is produced by Cellceutix.